Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaukosGKOS +0.32%64 Days Sales Outstanding is 63.56 as of Jun. 2026, which is 44% above its 10-year median of 44.00. GuruFocus rates GKOS with a GF Score™ of 64/100 and a GF Value™ of $148.83 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Glaukos ranks worse than 50.37% on this metric.
Glaukos's average Accounts Receivable for the
three
months ended in Jun. 2026 was $129.3 Mil. Glaukos's Revenue for the
three
months ended in Jun. 2026 was $185.6 Mil.
Hence, Glaukos's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 63.56.
The historical rank and industry rank for Glaukos's Days Sales Outstanding or its related term are showing as below:
GKOS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.86 Med: 44 Max: 65.38
Current: 65.38
During the past 13 years, Glaukos's highest Days Sales Outstanding was 65.38. The lowest was 34.86. And the median was 44.00.
GKOS's Days Sales Outstanding is ranked worse than 50.37% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs GKOS: 65.38
Glaukos's Days Sales Outstanding
increased
from Jun. 2025 (56.80) to Jun. 2026 (63.56).
Glaukos (NYSE:GKOS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Glaukos Days Sales Outstanding Related Terms
Glaukos Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Glaukos's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKOS vs BRKR, BIO, GMED: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Glaukos's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Glaukos's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (GKOS) has a Days Sales Outstanding of 63.56 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Glaukos and its competitors. This is 44% above median its historical median of 44.00. Over the past decade, Glaukos' Days Sales Outstanding has ranged from 34.86 to 65.38. According to the industry distribution chart, Glaukos ranks #409 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 50.4%.
Is Glaukos' Days Sales Outstanding too high?
Glaukos' current Days Sales Outstanding of 63.56 is 44% above median its 10-year median of 44.00. Over the past 10 years, this metric has ranged from a low of 34.86 to a high of 65.38. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. Glaukos' value of 63.56 is 2.5% below this industry median. Based on the distribution chart, Glaukos ranks #409 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Glaukos has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Days Sales Outstanding compare to BRKR and BIO?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #409 out of 812 companies for Days Sales Outstanding. This places Glaukos in the lower half of its industry. The industry median Days Sales Outstanding is 65.17. Glaukos' value of 63.56 is 2.5% below this benchmark. Historically, Glaukos' own Days Sales Outstanding has ranged from 34.86 to 65.38 over the past decade. While the company's 10-year median is 44.00 vs. the industry median of 65.17, Glaukos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glaukos's current Days Sales Outstanding of 63.56 is 2.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current Days Sales Outstanding is 63.56, which is 44% above median its own 10-year median of 44.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $148.83, compared to a current price of $182.00 — trading 22.3% above its estimated fair value. The current Days Sales Outstanding is 63.56, which is 44% above median its 10-year median of 44.00 and 2.5% below the Medical Devices & Instruments industry median of 65.17. Glaukos' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Glaukos (GKOS), the current Days Sales Outstanding is 63.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $182.00 is trading 22.3% above its estimated GF Value™ of $148.83.
GuruFocus considers Glaukos to be Modestly Overvalued.
Key valuation signals for GKOS:
Days Sales Outstanding: 63.56 (44% above median its 10-year median of 44.00)
GF Value™: $148.83 vs. price of $182.00 (22.3% above fair value)
Industry Position: 2.5% below the Medical Devices & Instruments median (#409 of 812)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
64GF Score
Get the complete analysis for GKOS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
